Global MRD (Minimal Residual Disease) Testing Market Research Report 2021

1 MRD (Minimal Residual Disease) Testing Market Overview

• 1.1 Product Overview and Scope of MRD (Minimal Residual Disease) Testing
• 1.2 MRD (Minimal Residual Disease) Testing Segment by Type
  • 1.2.1 Global MRD (Minimal Residual Disease) Testing Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 Flow Cytometry
  • 1.2.3 Polymerase Chain Reaction (PCR)
  • 1.2.4 Next-Generation Sequencing (NGS)
• 1.3 MRD (Minimal Residual Disease) Testing Segment by Application
  • 1.3.1 Global MRD (Minimal Residual Disease) Testing Sales Comparison by Application: (2021-2027)
  • 1.3.2 Specialty Clinics and Hospitals
  • 1.3.3 Diagnostic Laboratories
  • 1.3.4 Research Institutions
• 1.4 Global MRD (Minimal Residual Disease) Testing Market Size Estimates and Forecasts
  • 1.4.1 Global MRD (Minimal Residual Disease) Testing Revenue 2016-2027
  • 1.4.2 Global MRD (Minimal Residual Disease) Testing Sales 2016-2027
  • 1.4.3 MRD (Minimal Residual Disease) Testing Market Size by Region: 2016 Versus 2021 Versus 2027

2 MRD (Minimal Residual Disease) Testing Market Competition by Manufacturers

• 2.1 Global MRD (Minimal Residual Disease) Testing Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global MRD (Minimal Residual Disease) Testing Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers MRD (Minimal Residual Disease) Testing Manufacturing Sites, Area Served, Product Type
• 2.5 MRD (Minimal Residual Disease) Testing Market Competitive Situation and Trends
  • 2.5.1 MRD (Minimal Residual Disease) Testing Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest MRD (Minimal Residual Disease) Testing Players Market Share by Revenue
  • 2.5.3 Global MRD (Minimal Residual Disease) Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 MRD (Minimal Residual Disease) Testing Retrospective Market Scenario by Region

• 3.1 Global MRD (Minimal Residual Disease) Testing Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.2 Global MRD (Minimal Residual Disease) Testing Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.3 North America MRD (Minimal Residual Disease) Testing Market Facts & Figures by Country
  • 3.3.1 North America MRD (Minimal Residual Disease) Testing Sales by Country
  • 3.3.2 North America MRD (Minimal Residual Disease) Testing Revenue by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe MRD (Minimal Residual Disease) Testing Market Facts & Figures by Country
  • 3.4.1 Europe MRD (Minimal Residual Disease) Testing Sales by Country
  • 3.4.2 Europe MRD (Minimal Residual Disease) Testing Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific MRD (Minimal Residual Disease) Testing Market Facts & Figures by Region
  • 3.5.1 Asia Pacific MRD (Minimal Residual Disease) Testing Sales by Region
  • 3.5.2 Asia Pacific MRD (Minimal Residual Disease) Testing Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America MRD (Minimal Residual Disease) Testing Market Facts & Figures by Country
  • 3.6.1 Latin America MRD (Minimal Residual Disease) Testing Sales by Country
  • 3.6.2 Latin America MRD (Minimal Residual Disease) Testing Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa MRD (Minimal Residual Disease) Testing Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa MRD (Minimal Residual Disease) Testing Sales by Country
  • 3.7.2 Middle East and Africa MRD (Minimal Residual Disease) Testing Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 UAE

4 Global MRD (Minimal Residual Disease) Testing Historic Market Analysis by Type

• 4.1 Global MRD (Minimal Residual Disease) Testing Sales Market Share by Type (2016-2021)
• 4.2 Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Type (2016-2021)
• 4.3 Global MRD (Minimal Residual Disease) Testing Price by Type (2016-2021)

5 Global MRD (Minimal Residual Disease) Testing Historic Market Analysis by Application

• 5.1 Global MRD (Minimal Residual Disease) Testing Sales Market Share by Application (2016-2021)
• 5.2 Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Application (2016-2021)
• 5.3 Global MRD (Minimal Residual Disease) Testing Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 ICON plc
  • 6.1.1 ICON plc Corporation Information
  • 6.1.2 ICON plc Description and Business Overview
  • 6.1.3 ICON plc MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 ICON plc MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.1.5 ICON plc Recent Developments/Updates
• 6.2 ArcherDX(Invitae)
  • 6.2.1 ArcherDX(Invitae) Corporation Information
  • 6.2.2 ArcherDX(Invitae) Description and Business Overview
  • 6.2.3 ArcherDX(Invitae) MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 ArcherDX(Invitae) MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.2.5 ArcherDX(Invitae) Recent Developments/Updates
• 6.3 ARUP Laboratories
  • 6.3.1 ARUP Laboratories Corporation Information
  • 6.3.2 ARUP Laboratories Description and Business Overview
  • 6.3.3 ARUP Laboratories MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 ARUP Laboratories MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.3.5 ARUP Laboratories Recent Developments/Updates
• 6.4 Asuragen
  • 6.4.1 Asuragen Corporation Information
  • 6.4.2 Asuragen Description and Business Overview
  • 6.4.3 Asuragen MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Asuragen MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.4.5 Asuragen Recent Developments/Updates
• 6.5 Cergentis B.V.
  • 6.5.1 Cergentis B.V. Corporation Information
  • 6.5.2 Cergentis B.V. Description and Business Overview
  • 6.5.3 Cergentis B.V. MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 Cergentis B.V. MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.5.5 Cergentis B.V. Recent Developments/Updates
• 6.6 Bio-Rad Laboratories
  • 6.6.1 Bio-Rad Laboratories Corporation Information
  • 6.6.2 Bio-Rad Laboratories Description and Business Overview
  • 6.6.3 Bio-Rad Laboratories MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 Bio-Rad Laboratories MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.6.5 Bio-Rad Laboratories Recent Developments/Updates
• 6.7 Mission Bio
  • 6.6.1 Mission Bio Corporation Information
  • 6.6.2 Mission Bio Description and Business Overview
  • 6.6.3 Mission Bio MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Mission Bio MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.7.5 Mission Bio Recent Developments/Updates
• 6.8 Guardant Health
  • 6.8.1 Guardant Health Corporation Information
  • 6.8.2 Guardant Health Description and Business Overview
  • 6.8.3 Guardant Health MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.8.4 Guardant Health MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.8.5 Guardant Health Recent Developments/Updates
• 6.9 Invivoscribe
  • 6.9.1 Invivoscribe Corporation Information
  • 6.9.2 Invivoscribe Description and Business Overview
  • 6.9.3 Invivoscribe MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.9.4 Invivoscribe MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.9.5 Invivoscribe Recent Developments/Updates
• 6.10 LabCorp
  • 6.10.1 LabCorp Corporation Information
  • 6.10.2 LabCorp Description and Business Overview
  • 6.10.3 LabCorp MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.10.4 LabCorp MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.10.5 LabCorp Recent Developments/Updates
• 6.11 Inivata
  • 6.11.1 Inivata Corporation Information
  • 6.11.2 Inivata MRD (Minimal Residual Disease) Testing Description and Business Overview
  • 6.11.3 Inivata MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.11.4 Inivata MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.11.5 Inivata Recent Developments/Updates
• 6.12 Natera
  • 6.12.1 Natera Corporation Information
  • 6.12.2 Natera MRD (Minimal Residual Disease) Testing Description and Business Overview
  • 6.12.3 Natera MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.12.4 Natera MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.12.5 Natera Recent Developments/Updates
• 6.13 NeoGenomics Laboratories
  • 6.13.1 NeoGenomics Laboratories Corporation Information
  • 6.13.2 NeoGenomics Laboratories MRD (Minimal Residual Disease) Testing Description and Business Overview
  • 6.13.3 NeoGenomics Laboratories MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.13.4 NeoGenomics Laboratories MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.13.5 NeoGenomics Laboratories Recent Developments/Updates
• 6.14 Opko Health
  • 6.14.1 Opko Health Corporation Information
  • 6.14.2 Opko Health MRD (Minimal Residual Disease) Testing Description and Business Overview
  • 6.14.3 Opko Health MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.14.4 Opko Health MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.14.5 Opko Health Recent Developments/Updates
• 6.15 Quest Diagnostics
  • 6.15.1 Quest Diagnostics Corporation Information
  • 6.15.2 Quest Diagnostics MRD (Minimal Residual Disease) Testing Description and Business Overview
  • 6.15.3 Quest Diagnostics MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.15.4 Quest Diagnostics MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.15.5 Quest Diagnostics Recent Developments/Updates
• 6.16 Sysmex Corporation
  • 6.16.1 Sysmex Corporation Corporation Information
  • 6.16.2 Sysmex Corporation MRD (Minimal Residual Disease) Testing Description and Business Overview
  • 6.16.3 Sysmex Corporation MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.16.4 Sysmex Corporation MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.16.5 Sysmex Corporation Recent Developments/Updates
• 6.17 Adaptive Biotechnologies
  • 6.17.1 Adaptive Biotechnologies Corporation Information
  • 6.17.2 Adaptive Biotechnologies MRD (Minimal Residual Disease) Testing Description and Business Overview
  • 6.17.3 Adaptive Biotechnologies MRD (Minimal Residual Disease) Testing Sales, Revenue and Gross Margin (2016-2021)
  • 6.17.4 Adaptive Biotechnologies MRD (Minimal Residual Disease) Testing Product Portfolio
  • 6.17.5 Adaptive Biotechnologies Recent Developments/Updates

7 MRD (Minimal Residual Disease) Testing Manufacturing Cost Analysis

• 7.1 MRD (Minimal Residual Disease) Testing Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of MRD (Minimal Residual Disease) Testing
• 7.4 MRD (Minimal Residual Disease) Testing Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 MRD (Minimal Residual Disease) Testing Distributors List
• 8.3 MRD (Minimal Residual Disease) Testing Customers

9 MRD (Minimal Residual Disease) Testing Market Dynamics

• 9.1 MRD (Minimal Residual Disease) Testing Industry Trends
• 9.2 MRD (Minimal Residual Disease) Testing Growth Drivers
• 9.3 MRD (Minimal Residual Disease) Testing Market Challenges
• 9.4 MRD (Minimal Residual Disease) Testing Market Restraints

10 Global Market Forecast

• 10.1 MRD (Minimal Residual Disease) Testing Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of MRD (Minimal Residual Disease) Testing by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of MRD (Minimal Residual Disease) Testing by Type (2022-2027)
• 10.2 MRD (Minimal Residual Disease) Testing Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of MRD (Minimal Residual Disease) Testing by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of MRD (Minimal Residual Disease) Testing by Application (2022-2027)
• 10.3 MRD (Minimal Residual Disease) Testing Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of MRD (Minimal Residual Disease) Testing by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of MRD (Minimal Residual Disease) Testing by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List